Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.
This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.
Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier revisits a patient case study where a biologic has been added to an asthma management plan and describes the potential for this patient to achieve on-therapy clinical remission.
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.